Advantage Alpha Capital Partners LP Has $176,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Advantage Alpha Capital Partners LP decreased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 56.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,890 shares of the company's stock after selling 11,477 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in Kiniksa Pharmaceuticals were worth $176,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $1,192,000. JPMorgan Chase & Co. acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth $4,997,000. Parkman Healthcare Partners LLC grew its stake in shares of Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company's stock worth $18,874,000 after purchasing an additional 108,102 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at $675,000. Finally, SG Americas Securities LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at about $355,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ KNSA traded down $0.27 during mid-day trading on Friday, hitting $23.09. 1,544,612 shares of the company traded hands, compared to its average volume of 445,442. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $16.56 and a 1 year high of $28.15. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -164.92 and a beta of 0.48. The business has a 50 day moving average of $20.77 and a two-hundred day moving average of $22.00.

Remove Ads

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. During the same quarter in the previous year, the business earned $0.35 earnings per share. The business's quarterly revenue was up 46.9% compared to the same quarter last year. As a group, research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 11,464 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, March 17th. The shares were sold at an average price of $23.10, for a total transaction of $264,818.40. Following the completion of the sale, the chief financial officer now owns 23,382 shares of the company's stock, valued at $540,124.20. This trade represents a 32.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. This trade represents a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,766 shares of company stock valued at $2,011,735. Company insiders own 54.57% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price for the company. Wedbush reiterated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.